{
  "eval_id": "S43",
  "eval_file": "evals/single/S43.json",
  "timestamp": "2025-09-18T16:54:55.196551Z",
  "model": "gpt-4.1",
  "temperature": 0.6,
  "rep_input": "Patient HR+/HER2- progressed after CDK4/6; what key label-based caveats should I discuss?",
  "model_output": "After progression on CDK4/6 in HR+/HER2- disease, label-based choices focus on approved endocrine partners or chemotherapy, considering prior agents, patient fitness, and organ involvement. Tolerability and specific contraindications from the SmPC should guide discussionâ€”please send the relevant EMA-approved label for reference."
}